Retroperitoneal sarcomas are rare neoplasms that often present with multivisceral involvement. Treatment for these tumors requires careful decision making requiring a combination of surgery, chemotherapy, and radiation therapy.
Methods
We reviewed the scientific literature pertaining to the diagnosis and management of retroperitoneal sarcomas. We also identify recent developments in treatment and discuss future trends in the care of patients with this disease.
Results
Retroperitoneal tumors often present as large, locally advanced lesions. Evaluation of these tumors requires careful consideration of a multimodality approach. Retrospective data and historical prospective series have demonstrated the survival benefit of radical resection for these tumors with en bloc resection of involved structures. Compartmental resections in the retroperitoneum along with debulking of high-grade disease and regional therapy are controversial approaches with significant morbidity that can lead to long-term survival. The application of neoadjuvant and adjuvant therapies in select tumor histologies may improve local control and survival.
Conclusions
The management of retroperitoneal sarcomas requires a multidisciplinary approach and is best accomplished at high-volume centers specializing in the care of patients with these complex malignancies. Current data suggest that radical resection remains the only chance for cure and that chemotherapy and radiation therapy may confer a survival benefit.
Fabre-GuillevinE., CoindreJ.M., Somerhausen NdeS.. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas.Cancer.2006; 106(12): 2725–2733.
7.
SingerS., AntonescuC.R., RiedelE.. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.Ann Surg.2003; 238(3): 358–370; discussion 370-371.
8.
ItalianoA., ToulmondeM., StoeckleE.. Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin.Ann Oncol.2010; 21(9): 1915–1921.
9.
BerthetB., SugarbakerT.A., ChangD.. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.Eur J Cancer.1999; 35(3): 413–419.
10.
De PasT., ToffalorioF., ColomboP.. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.J Thorac Oncol.2008; 3(8): 938–941.
11.
HeslinM.J., LewisJ.J., NadlerE.. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management.J Clin Oncol.1997; 15(8): 2832–2839.
12.
HuangH.Y., BrennanM.F., SingerS.. Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation.Mod Pathol.2005; 18(7): 976–984.
13.
KraybillW.G., HarrisJ., SpiroI.J.. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.J Clin Oncol.2006; 24(4): 619–625.
14.
SingerS., CorsonJ.M., DemetriG.D.. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.Ann Surg.1995; 221(2): 185–195.
15.
DalalK.M., KattanM.W., AntonescuC.R.. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk.Ann Surg.2006; 244(3): 381–391.
16.
LahatG., DhukaA.R., LahatS.. Outcome of locally recurrent and metastatic angiosarcoma.Ann Surg Oncol.2009; 16(9): 2502–2509.
17.
AnayaD.A., LahatG., LiuJ.. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making.Ann Surg.2009; 249(1): 137–142.
18.
ShibataD., LewisJ.J., LeungD.H.. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas?J Am Coll Surg.2001; 193(4): 373–379.
19.
DaylamiR., AmiriA., GoldsmithB.. Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection?J Am Coll Surg.2010; 210(2): 185–190.
20.
PistersP.W., BalloM.T., FenstermacherM.J.. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.J Clin Oncol.2003; 21(16): 3092–3097.
21.
GieschenH.L., SpiroI.J., SuitH.D.. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma.Int J Radiat Oncol Biol Phys.2001; 50(1): 127–131.
22.
BonvalotS., RivoireM., CastaingM.. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.J Clin Oncol.2009; 27(1): 31–37.
23.
GronchiA., Lo VulloS., FioreM.. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients.J Clin Oncol.2009; 27(1): 24–30.
24.
RussoP., KimY., RavindranS.. Nephrectomy during operative management of retroperitoneal sarcoma.Ann Surg Oncol.1997; 4(5): 421–424.
25.
StaufferJ.A., FakhreG.P., DoughertyM.K.. Pancreatic and multiorgan resection with inferior vena cava reconstruction for retroperitoneal leiomyosarcoma.World J Surg Oncol.2009; 7: 3.
26.
DewJ., HansenK., HammonJ.. Leiomyosarcoma of the inferior vena cava: surgical management and clinical results.Am Surg.2005; 71(6): 497–501.
27.
HollenbeckS.T., GrobmyerS.R., KentK.C.. Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma.J Am Coll Surg.2003; 197(4): 575–579.
28.
MingoliA., FeldhausR.J., CavallaroA.. Leiomyosarcoma of the inferior vena cava: analysis and search of world literature on 141 patients and report of three new cases.J Vasc Surg.1991; 14(5): 688–699.
29.
GutierrezJ.C., PerezE.A., MoffatF.L.. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients.Ann Surg.2007; 245(6): 952–958.
30.
LewisJ.J., LeungD., WoodruffJ.M.. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.Ann Surg.1998; 228(3): 355–365.
31.
EilberF.C., RosenG., EckardtJ.. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.J Clin Oncol.2001; 19(13): 3203–3209.
32.
MericF., HessK.R., VarmaD.G.. Radiographic response to neo-adjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.Cancer.2002; 95(5): 1120–1126.
33.
VermaS., YounusJ., Stys-NormanD.. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.Cancer Treat Rev.2008; 34(4): 339–347.
34.
CaudleA.S., TepperJ.E., CalvoB.F.. Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas.Ann Surg Oncol.2007; 14(2): 577–582.
35.
MericF., MilasM., HuntK.K.. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.J Clin Oncol.2000; 18(19): 3378–3383.
FrustaciS., GherlinzoniF., De PaoliA.. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.J Clin Oncol.2001; 19(5): 1238–1247.
39.
ItalianoA., DelvaF., Mathoulin-PelissierS.. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.Ann Oncol.2010; 21(12): 2436–2441.
40.
SugarbakerP.H.. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.Semin Surg Oncol.1998; 14(3): 254–261.
41.
BonvalotS., CavalcantiA., Le PéchouxC.. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.Eur J Surg Oncol.2005; 31(8): 917–923.
42.
EilberF.C., RosenG., ForscherC.. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas.Ann Surg Oncol.1999; 6(7): 645–650.
43.
LimS.J., CormierJ.N., FeigB.W.. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.Ann Surg Oncol.2007; 14(8): 2309–2318.
44.
RossiC.R., FolettoM., MocellinS.. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.Cancer.2002; 94(2): 492–499.
45.
RossiC.R., DeracoM., De SimoneM.. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.Cancer.2004; 100(9): 1943–1950.
46.
EsquivelJ., StojadinovicA., LevineE.A.. The American Society of Peritoneal Surface Malignancies (ASPSM).Ann Surg Oncol.2010 Nov 11. Epub ahead of print.
47.
PistersP.W., HarrisonL.B., LeungD.H.. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.J Clin Oncol.1996; 14(3): 859–868.
48.
YangJ.C., ChangA.E., BakerA.R.. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.J Clin Oncol.1998; 16(1): 197–203.
49.
AlektiarK.M., BrennanM.F., HealeyJ.H.. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity.J Clin Oncol.2008; 26(20): 3440–3444.
50.
KoshyM., RichS.E., MohiuddinM.M.. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis.Int J Radiat Oncol Biol Phys.2010; 77(1): 203–209.
51.
BalloM.T., ZagarsG.K., PollockR.E.. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment.Int J Radiat Oncol Biol Phys.2007; 67(1): 158–163.
52.
TzengC.W., FiveashJ.B., PoppleR.A.. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma.Cancer.2006; 107(2): 371–379.
53.
JonesJ.J., CattonC.N., O'SullivanB.. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.Ann Surg Oncol.2002; 9(4): 346–354.
54.
YoonS.S., ChenY.L., KirschD.G.. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas.Ann Surg Oncol.2010; 17(6): 1515–1529.
55.
ParkJ.O., QinL.X., PreteF.P.. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.Ann Surg.2009; 250(6): 977–982.
56.
BlackmonS.H., NipamS., RothJ.. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival.Ann Thorac Surg.2009; 88(3): 877–885.
57.
MarudanayagamR., SandhuB., PereraM.T.. Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors.Eur J Surg Oncol.2011; 37(1): 87–92.
58.
ChenH., PruittA., NicolT.L.. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival.J Gastrointest Surg.1998; 2(2): 151–155.
59.
RehdersA., PeiperM., StoeckleinN.H.. Hepatic metastasectomy for soft-tissue sarcomas: is it justified?World J Surg.2009; 33(1): 111–117.
60.
ReddyS.K., BarbasA.S., MarroquinC.E.. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis.J Am Coll Surg.2007; 204(3): 372–382.
61.
YehJ.J., SingerS., BrennanM.F.. Effectiveness of palliative procedures for intra-abdominal sarcomas.Ann Surg Oncol.2005; 12(12): 1084–1089.
